Bariatric Surgery and Pharmacokinetics of Escitalopram

Norwegian University of Science and Technology12 enrolled

Overview

Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on escitalopram are investigated.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Obesity, Morbid

Interventions

EscitalopramDRUG

Patients are tested for their normal prescription escitalopram medication

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Preparing to undergo gastric bypass or sleeve gastrectomy in Central Norway * Being a Norwegian citizen Exclusion Criteria: * Having previously undergone resections in the GI-tract

Locations (1)

St. Olavs University Hospital

Trondheim, Norway

RECRUITING

Outcomes

Primary Outcomes

Escitalopram concentration in blood serum (area under curve (AUC))

Time frame: From baseline to 1 year postoperatively

Central Contacts

Magnus Strømmen, MSc

CONTACT

0047 72829970 magnus.strommen@stolav.no

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.